Courses by Plexus Communications (55)
-
Plexus Communications +1 Beyond BCMA: Exploring GPRC5D-Directed CAR T-Cell Therapies in Relapsed/Refractory Multiple Myeloma
-
Plexus Communications +1 Optimizing the Use of Bispecific Antibodies in Relapsed or Refractory Multiple Myeloma Across the VA Healthcare System
-
Plexus Communications +1 Advancing EGFR-Mutated NSCLC Management Across Practice Settings: Evidence-Based Approaches to Testing, Treatment Selection, and Sequencing
-
Plexus Communications +1 Optimizing Checkpoint Inhibitor Therapy for Advanced Hepatobiliary Cancers
-
Plexus Communications +1 New Additions to the Neuroendocrine Tumor Treatment Arsenal: Essential Advances in Targeted Therapy & Nuclear Medicine
-
Plexus Communications +1 CELMoDs for Multiple Myeloma in the Veterans Administration: Optimizing RRMM Treatment With Potent Immunomodulatory Drugs
-
Plexus Communications +1 Maintenance Therapy Milestones in Ovarian Cancer: Maximizing the Benefits of PARP Inhibition
-
Plexus Communications +1 Targeting HER2 in Advanced NSCLC: Translating Evidence Into Equitable, Personalized Care for Veterans
-
Plexus Communications +1 Targeting EGFR in NSCLC: Evidence-Based Strategies Across Stages, Sequencing, and Resistance in Veterans Health Administration Practice Settings
-
Plexus Communications +1 AKT Pathway Targeting in Metastatic Hormone-Sensitive Prostate Cancer: Practical Insights for VA Clinicians
-
Plexus Communications +1 Pathways to Practice Change: Leveraging Advances in BTKi-Based Treatment Regimens for Veterans with Chronic Lymphocytic Leukemias
-
Plexus Communications +1 Immunotherapy in Bladder Cancer: Bringing Practice-Changing Advancements into Clinical Practice
-
Plexus Communications +1 Optimizing Treatment Sequencing in Cutaneous T-Cell Lymphoma: New Evidence, New Guidelines, and Practical Decision-Making
-
Plexus Communications +1 Transforming Care in Pancreatic Ductal Adenocarcinoma: Emerging Evidence and Clinical Implications
-
Plexus Communications +1 Contemporary B-ALL Care: Practical Integration and Use of CD19-Directed Bispecific Antibodies
-
Plexus Communications +1 Bringing BTK Inhibitors to the Frontline Setting: Essential Advancements in Mantle Cell Lymphoma Management
-
Plexus Communications +1 Bridging CAR T-Cell Therapy Into Community Practice: Optimizing Care for Patients With Non-Hodgkin Lymphoma
-
Plexus Communications +1 Navigating Transformations in the Squamous, Non-Small Cell Lung Cancer Treatment Landscape: Implications for VA Healthcare Systems
-
Plexus Communications +1 Beyond BCMA: Exploring GPRC5D-Directed CAR T-Cell Therapies in Relapsed/Refractory Multiple Myeloma
-
Plexus Communications +1 Beyond BCMA: Exploring GPRC5D-Directed CAR T-Cell Therapies in Relapsed/Refractory Multiple Myeloma
-
Plexus Communications +1 VHA Oncology Clinical Forums: Optimizing BTK Inhibitor Use in the Management of Veterans With Chronic Lymphocytic Leukemia
-
Plexus Communications +1 Raising the Bar for Hodgkin Lymphoma: Optimizing Immunotherapy in Community Practice
-
Plexus Communications +1 Blueprints for Better Outcomes: BTK Inhibitors for Specific DLBCL Biological Subtypes
-
Plexus Communications +1 Optimizing the Use of Bispecific Antibodies in Relapsed or Refractory Multiple Myeloma Across the VA Healthcare System